Am­gen on IRA's drug price ne­go­ti­a­tions: 'Ma­te­r­i­al ad­verse ef­fec­t' on sales, busi­ness and op­er­a­tions

Bi­o­log­ic pow­er­house Am­gen is mak­ing clear that Pres­i­dent Biden’s sig­na­ture law au­tho­riz­ing Medicare drug price ne­go­ti­a­tions is go­ing to have a neg­a­tive im­pact on the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER